Our highly predictive and non-invasive prognostic/diagnostic applications have the potential to fundamentally improve the treatment of disease

Publications

3-Dimensional Telomere Technology

Telomeres are sections of DNA at the ends of chromosomes that act as protective caps. Healthy telomeres safeguard the entire genome, regulating cell division and maintaining its integrity and stability.

Dysfunction or loss of telomeres leads to genome alterations such as chromosomal fusions, uncontrolled cell growth and genomic instability; which is a causal factor in the development of genetic diseases including cancer and neurodegenerative diseases (CNS).

Our proprietary technology TeloView®, quantifies genomic instability by measuring the 3D structure and the spatial organization of telomeres. It is designed to provide important actionable information regarding the aggressiveness of disease and potential response to treatment.

Telo Genomics Product Offering in Multiple Myeloma

TeloViewSMM
‍

SMM Patients with
High Risk of
Transition to MM

TeloViewNDMM
‍

Predicts Newly Diagnosed MM Patients who may Relapse on 1st Line Therapy

TeloMRD-D Enumeration

Identification & Enumeration of MRD Cells in Post Transplant Patients

TeloViewNG-MRD Profiling

Genomic Instability Profiling of MRD Detected Cells in Post Transplant Patients

TeloViewSMM

SMM Patients with
High Risk of
Transition to MM
  • Clinically Validated and Available as a CLIA test
  • Physician Experience Program (SMART Program) Ongoing Download the SMART Program Brochure
  • TeloViewSMM is an Approved LDT on Telo’s CAP/CLIA & ISO 15189 Testing Menu

To know more about
‍TeloViewSMM

TeloViewNDMM

Predicts Newly Diagnosed
MM Patients who may
Relapse on
1st Line Therapy
  • Predictive Modeling Completed
  • Independent Retrospective Validation Ongoing
  • Accuracy: 82%;
    Sensitivity: 85%;
    Specificity: 72%
  • Potential Utility to Qualify NDMM Patients who Failed 1st Line Therapy for CAR-T Treatment

To know more about
‍TeloViewNDMM

TeloMRD-D
Enumeration

Identification & Enumeration
of MRD cells in
Post Transplant Patients
  • Superior Sensitivity by at least 1 Order of Magnitude Compared to Other Technologies
  • Clinical Trial in Progress
  • Clinical Validation with Adaptive MRD Enumeration Technology (ClonoSEQ)– in Progress

To know more about
‍TeloMRD-D

TeloViewNG
-MRD Profiling

Genomic Instability Profiling
of MRD Detected Cells
in Post Transplant
Patients
  • Clinical Trial in Progress, in Collaboration with Jewish General Hospital/ McGill University, Canada

To know more about
‍TeloViewNG-MRD

MRD Assessment is a Game Changer in Cancer Prognostics with Expanding Market Expect to Reach 4.1 Billion by 2032

To Know More AboutTeloViewSMM

To Know More AboutTeloViewNDMM

To Know More AboutTeloMRD-D

To Know More AboutTeloViewNG-MRD

416-673-8487
info@telodx.com
Company
HomeAbout UsBackgroundCollaboratorsAccreditationInvestors
Technology
Telomere ScienceTeloView®Conference PresentationsPublicationsIP
Multiple Myeloma
OverviewSmoldering Multiple MyelomaMRD SolutionsMayo Clinic
Contact Us
InquiriesCareers
MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, Ontario, Canada M5G 1L7
(c) 2023 Telo Genomics. All rights reserved.
Powered by Cherry Creative Group